TQ05310 is an orally available inhibitor of IDH2 mutants, targeting both IDH2-R140Q ( IC 50 =136.9 nM) and IDH2-R172K ( IC 50 =37.9 nM) mutants. TQ05310 inhibits the production of 2-hydroxyglutarate (2-HG) and induces differentiation of cells expressing IDH2-R140Q and IDH2-R172K by inhibiting the enzymatic activity of mutant IDH2. TQ05310 can be used for the study of acute myeloid leukemia.